Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.
Monoclonal Gammopathy of Undetermined Significance|Smoldering Plasma Cell Myeloma
OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration
Quality of life questionnaires, Patients complete quality of life questionnaires over 10-15 minutes at baseline.

Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time, Up to 3 years|Quality of life questionnaires, Patients complete quality of life questionnaires every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.

Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time, Up to 3 years
PRIMARY OBJECTIVE:

I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM already participating in clinical trials at MD Anderson Cancer Center.

SECONDARY OBJECTIVE:

I. Identify the most common symptoms/patients concerns to evaluate future interventions for treatment/prevention in this population.

OUTLINE:

Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.